Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization

A. Gradilone, G. Naso, C. Raimondi, E. Cortesi, O. Gandini, B. Vincenzi, R. Saltarelli, E. Chiapparino, F. Spremberg, M. Cristofanilli, L. Frati, A. M. Aglianò, P. Gazzaniga

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Background: The expression of ATP-binding cassette transporters on circulating tumor cells (CTCs) is predictive of response to chemotherapy in cancer patients. We tested the hypothesis that drug-resistant CTCs might have predictive value in metastatic breast cancer (MBC) and possibly retain stem-like properties. Patients and methods: CTCs obtained from 42 MBC patients were evaluated for multidrug-resistance-related proteins (MRPs), aldehyde dehydrogenase 1 (ALDH1), estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2/neu). Primary objective was to evaluate the prognostic and predictive value of CTCs profile. Secondary end points were the level of concordance in ERα and HER2/neu status between primary tumors and CTCs and the correlation in CTCs between ALDH1, drug resistance profile and number of MRPs. Results: A difference in progression-free survival (PFS) was found between CTCs-positive and CTCs-negative patients. PFS was shorter in patients with a 'drug resistance' CTCs profile and in patients whose CTCs expressed two or more MRPs. No correlation was found between tumor characteristics and ALDH1. ALDH1 correlated to negative ERα and positive HER2/neu status in CTCs. The correlation between the number of MRPs expressed in CTCs and ALDH1 was statistically significant. Conclusion: In MBC, the presence of CTCs expressing MRPs and ALDH1 is predictive of response to chemotherapy.

Original languageEnglish
Pages (from-to)86-92
Number of pages7
JournalAnnals of Oncology
Volume22
Issue number1
DOIs
Publication statusPublished - 2011

Fingerprint

Circulating Neoplastic Cells
Drug Resistance
Breast Neoplasms
P-Glycoproteins
Estrogen Receptors
Disease-Free Survival
Drug Therapy
Neoplasms
ATP-Binding Cassette Transporters
aldehyde dehydrogenase 1

Keywords

  • Breast cancer
  • Cancer stem cells
  • Circulating tumor cells
  • Drug resistance

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Gradilone, A., Naso, G., Raimondi, C., Cortesi, E., Gandini, O., Vincenzi, B., ... Gazzaniga, P. (2011). Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization. Annals of Oncology, 22(1), 86-92. https://doi.org/10.1093/annonc/mdq323

Circulating tumor cells (CTCs) in metastatic breast cancer (MBC) : Prognosis, drug resistance and phenotypic characterization. / Gradilone, A.; Naso, G.; Raimondi, C.; Cortesi, E.; Gandini, O.; Vincenzi, B.; Saltarelli, R.; Chiapparino, E.; Spremberg, F.; Cristofanilli, M.; Frati, L.; Aglianò, A. M.; Gazzaniga, P.

In: Annals of Oncology, Vol. 22, No. 1, 2011, p. 86-92.

Research output: Contribution to journalArticle

Gradilone, A, Naso, G, Raimondi, C, Cortesi, E, Gandini, O, Vincenzi, B, Saltarelli, R, Chiapparino, E, Spremberg, F, Cristofanilli, M, Frati, L, Aglianò, AM & Gazzaniga, P 2011, 'Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization', Annals of Oncology, vol. 22, no. 1, pp. 86-92. https://doi.org/10.1093/annonc/mdq323
Gradilone, A. ; Naso, G. ; Raimondi, C. ; Cortesi, E. ; Gandini, O. ; Vincenzi, B. ; Saltarelli, R. ; Chiapparino, E. ; Spremberg, F. ; Cristofanilli, M. ; Frati, L. ; Aglianò, A. M. ; Gazzaniga, P. / Circulating tumor cells (CTCs) in metastatic breast cancer (MBC) : Prognosis, drug resistance and phenotypic characterization. In: Annals of Oncology. 2011 ; Vol. 22, No. 1. pp. 86-92.
@article{700be57b00624aeda857a0d9546178c9,
title = "Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): Prognosis, drug resistance and phenotypic characterization",
abstract = "Background: The expression of ATP-binding cassette transporters on circulating tumor cells (CTCs) is predictive of response to chemotherapy in cancer patients. We tested the hypothesis that drug-resistant CTCs might have predictive value in metastatic breast cancer (MBC) and possibly retain stem-like properties. Patients and methods: CTCs obtained from 42 MBC patients were evaluated for multidrug-resistance-related proteins (MRPs), aldehyde dehydrogenase 1 (ALDH1), estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2/neu). Primary objective was to evaluate the prognostic and predictive value of CTCs profile. Secondary end points were the level of concordance in ERα and HER2/neu status between primary tumors and CTCs and the correlation in CTCs between ALDH1, drug resistance profile and number of MRPs. Results: A difference in progression-free survival (PFS) was found between CTCs-positive and CTCs-negative patients. PFS was shorter in patients with a 'drug resistance' CTCs profile and in patients whose CTCs expressed two or more MRPs. No correlation was found between tumor characteristics and ALDH1. ALDH1 correlated to negative ERα and positive HER2/neu status in CTCs. The correlation between the number of MRPs expressed in CTCs and ALDH1 was statistically significant. Conclusion: In MBC, the presence of CTCs expressing MRPs and ALDH1 is predictive of response to chemotherapy.",
keywords = "Breast cancer, Cancer stem cells, Circulating tumor cells, Drug resistance",
author = "A. Gradilone and G. Naso and C. Raimondi and E. Cortesi and O. Gandini and B. Vincenzi and R. Saltarelli and E. Chiapparino and F. Spremberg and M. Cristofanilli and L. Frati and Aglian{\`o}, {A. M.} and P. Gazzaniga",
year = "2011",
doi = "10.1093/annonc/mdq323",
language = "English",
volume = "22",
pages = "86--92",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "1",

}

TY - JOUR

T1 - Circulating tumor cells (CTCs) in metastatic breast cancer (MBC)

T2 - Prognosis, drug resistance and phenotypic characterization

AU - Gradilone, A.

AU - Naso, G.

AU - Raimondi, C.

AU - Cortesi, E.

AU - Gandini, O.

AU - Vincenzi, B.

AU - Saltarelli, R.

AU - Chiapparino, E.

AU - Spremberg, F.

AU - Cristofanilli, M.

AU - Frati, L.

AU - Aglianò, A. M.

AU - Gazzaniga, P.

PY - 2011

Y1 - 2011

N2 - Background: The expression of ATP-binding cassette transporters on circulating tumor cells (CTCs) is predictive of response to chemotherapy in cancer patients. We tested the hypothesis that drug-resistant CTCs might have predictive value in metastatic breast cancer (MBC) and possibly retain stem-like properties. Patients and methods: CTCs obtained from 42 MBC patients were evaluated for multidrug-resistance-related proteins (MRPs), aldehyde dehydrogenase 1 (ALDH1), estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2/neu). Primary objective was to evaluate the prognostic and predictive value of CTCs profile. Secondary end points were the level of concordance in ERα and HER2/neu status between primary tumors and CTCs and the correlation in CTCs between ALDH1, drug resistance profile and number of MRPs. Results: A difference in progression-free survival (PFS) was found between CTCs-positive and CTCs-negative patients. PFS was shorter in patients with a 'drug resistance' CTCs profile and in patients whose CTCs expressed two or more MRPs. No correlation was found between tumor characteristics and ALDH1. ALDH1 correlated to negative ERα and positive HER2/neu status in CTCs. The correlation between the number of MRPs expressed in CTCs and ALDH1 was statistically significant. Conclusion: In MBC, the presence of CTCs expressing MRPs and ALDH1 is predictive of response to chemotherapy.

AB - Background: The expression of ATP-binding cassette transporters on circulating tumor cells (CTCs) is predictive of response to chemotherapy in cancer patients. We tested the hypothesis that drug-resistant CTCs might have predictive value in metastatic breast cancer (MBC) and possibly retain stem-like properties. Patients and methods: CTCs obtained from 42 MBC patients were evaluated for multidrug-resistance-related proteins (MRPs), aldehyde dehydrogenase 1 (ALDH1), estrogen receptor α (ERα) and human epidermal growth factor receptor 2 (HER2/neu). Primary objective was to evaluate the prognostic and predictive value of CTCs profile. Secondary end points were the level of concordance in ERα and HER2/neu status between primary tumors and CTCs and the correlation in CTCs between ALDH1, drug resistance profile and number of MRPs. Results: A difference in progression-free survival (PFS) was found between CTCs-positive and CTCs-negative patients. PFS was shorter in patients with a 'drug resistance' CTCs profile and in patients whose CTCs expressed two or more MRPs. No correlation was found between tumor characteristics and ALDH1. ALDH1 correlated to negative ERα and positive HER2/neu status in CTCs. The correlation between the number of MRPs expressed in CTCs and ALDH1 was statistically significant. Conclusion: In MBC, the presence of CTCs expressing MRPs and ALDH1 is predictive of response to chemotherapy.

KW - Breast cancer

KW - Cancer stem cells

KW - Circulating tumor cells

KW - Drug resistance

UR - http://www.scopus.com/inward/record.url?scp=78650328019&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650328019&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdq323

DO - 10.1093/annonc/mdq323

M3 - Article

C2 - 20603432

AN - SCOPUS:78650328019

VL - 22

SP - 86

EP - 92

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 1

ER -